Figure 3. In vitro sensitivity of the TF cells to the different drugs used to treat the patient; specific impact on downstream signaling pathways.

A) The activity of major signaling pathways (ERK, PI3K/AKT/mTOR/S6K) in response to the different treatments (sunitinib (Su), sorafenib (So) and everolimus (Ev)) was determined by analysis of the presence of the phosphorylated forms of the kinases (pERK, pAKT, pS6K) in TF cells following a short-term treatment (two hours) by immunoblotting. Tubulin is shown as a loading control. B) Quantification of the experiments shown in A. The percentage of phosphorylated kinases or their total amount is indicated with respect to the reference value (100%) for the cell without any inhibitor. These results are representative of four independent experiments.